Informations générales (source: ClinicalTrials.gov)

NCT02957760 Statut inconnu
Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydroxycarbamide Treatment. (PNPRO_HC)
Interventional
  • Occlusion veineuse rétinienne
Phase 2
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts (Voir sur ClinicalTrials)
décembre 2015
décembre 2017
29 juin 2024
The central retinal vein occlusion (CRVO) is a major cause of ocular morbidity, depending in particular on the occurrence and extent of retinal ischemia by capillary occlusion. There is no effective systemic treatment of this condition. An increase in the adhesion of erythrocytes to vascular endothelium was observed for patients with CRVO, correlated with overexpression of membrane phosphatidylserine
 Voir le détail

Etablissements

Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
CHNO DES QUINZE-VINGTS PARIS Laurent Vinet En recrutement IDF Contact (sur clinicalTrials)

Critères

Tous
Inclusion Criteria:

- Patients of both sexes of at least 45 years of age.

- with social protection

- Presenting CRVO for less than 1 month duration

- With a decrease of visual acuity and with the best corrected visual acuity lower
than 6/10 (73 ETDRS letters)

- Signature of informed consent


- predictable lack of compliance to the protocol

- monophtalmic patient or any ocular history or condition that could interfere with
the study course or results interpretation.

- active systemic disease

- sickle cell disease

- myeloproliferative disease

- myelosuppression

- kidney or liver insufficiency

- ongoing treatment with hydroxycarbamide or anticoagulant

- Pregnancy, breast-feeding, no efficient contraception (for both sexes)

- wish of paternity (for males of al least 45 years of age)